What is Viridian Therapeutics, Inc.'s debt issuance costs?

Viridian Therapeutics, Inc. (VRDN) reported debt issuance costs of $119.5K in Q4 2025.

What does debt issuance costs mean?

Cash paid for fees, legal costs, and underwriting discounts associated with issuing new debt.

Viridian Therapeutics, Inc. VRDN Debt Issuance Costs

Debt Issuance Costs at other companies

PVL

Palvella TherapeuticsPVLA

$14.25M—

TG TherapeuticsTGTX

$2.6M—

Arrowhead ResearchARWR

$18.72M—

BioCryst PharmaceuticalsBCRX

$4.95M—

BridgeBio PharmaBBIO

——

Other financials

Income statement

See full

Revenue$141.0K+95.8%

Operating income-$116.2M-23.8%

Net income-$104.9M-20.7%

EPS (diluted)-$1.15-5.5%

Balance sheet

See full

Cash & equivalents$176.3M+51.7%

Total debt$36.8M+59.4%

Total equity$636.0M+5.2%

Total assets$789.0M+19.4%

Cash flow

See full

Operating cash flow-$119.7M-29.1%

CapEx$23.0K-73.3%

Free cash flow-$119.7M-29.0%

Valuation

See full

Market cap$1.91B+82.0%

Profitability

See full

Gross margin36.3%—

Operating margin-543.9%-271pp

Net margin-508.5%-254pp

FCF margin-428.4%-214pp

Returns & leverage

See full

Return on equity-58.1%+7.9pp

Debt / equity0.1×0.0×

Current ratio15.1×-4.3×

Where this comes from

Reported directly by Viridian Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfDebtIssuanceCosts.

The official record: Viridian Therapeutics, Inc.’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viridian Therapeutics, Inc.'s debt issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Viridian Therapeutics, Inc.'s debt issuance costs?: Viridian Therapeutics, Inc. (VRDN) reported debt issuance costs of $119.5K in Q4 2025.
What does debt issuance costs mean?: Cash paid for fees, legal costs, and underwriting discounts associated with issuing new debt.